<DOC>
	<DOCNO>NCT00970593</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , activity OAP-189 subject type 2 diabetes take metformin diabetes .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability , And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects must diagnose type 2 diabetes , HbA1c level &gt; =7.0 % &lt; =11.0 % fast glucose level &lt; =280 mg/dL . Men woman nonchildbearing potential ( WONCBP ) , age 18 65 year inclusive study day 1 . Body mass index range 27 40kg/mÂ² ( inclusive ) body weight &gt; =50 kg . Subjects must otherwise generally healthy , may enrol stable chronic illness , well control interfere primary objective study . Subjects must currently treat diabetes metformin alone total daily dose &gt; =1gm ( administered QD BID ) dose must stable least 4 week study day 1 . Nonsmoker . Any significant disease exception diabetes mellitus . Any surgical medical condition may interfere absorption , distribution , metabolism , excretion investigational product . Acute disease state ( eg , nausea , vomit , fever , diarrhea ) within 7 day study day 1 . Any clinically important problem physical examination result , vitals sign measurement , ECGs , clinical laboratory test result . Positive serologic finding human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , and/or hepatitis C virus ( HCV ) antibody . Positive finding urine drug screen Use investigational nonpermitted prescription drug within 30 day investigational product administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>